During Monday’s Current trade, Shares of Celgene Corporation (NASDAQ:CELG), lost -0.36% to $128.77.
Celgene Corporation (CELG) declared that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to the formerly declared tender offer by its wholly-owned partner, Strix Corporation, for all issued and outstanding shares of common stock of Receptos, Inc. (RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes and subsequent merger of Strix Corporation with Receptos expired at 11:59 p.m. EDT on August 10, 2015. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Celgene anticipates the transaction to close in the third quarter of 2015.
The tender offer is planned to expire at midnight EDT on Monday, August 24, 2015, unless extended.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), traded showed no change to $16.27, during its current trading session.
Celldex Therapeutics, Inc. (CLDX) reported business and financial highlights for the second quarter ended June 30, 2015.
Program Updates:
RINTEGA(R) (“rindopepimut”; “rindo”; CDX-110), an EGFRvIII(v3)-specific therapeutic vaccine for glioblastoma (GBM)
- In June, the independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA(R) (rindopepimut) in patients with newly diagnosed glioblastoma as a result of a prespecified interim analysis assessing safety, futility and efficacy at 50% of events (deaths). The ACT IV study is a randomized, double-blind, placebo controlled study of RINTEGA plus GM-CSF added to standard of care temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. 745 patients were enrolled into ACT IV to reach the required 374 patients with minimal residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, counting those with disease that exceed this threshold, will be comprised of in a secondary analysis of overall survival in addition to analyses of progression-free survival, safety and tolerability, and quality of life. The second interim analysis is predictable to occur in late 2015/early 2016.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Jumei International Holding Ltd(ADR) (NYSE:JMEI), during its Monday’s current trading session gained 4.46% to $17.33.
International Holding Limited (JMEI) China’s leading online retailer of beauty products, recently declared that it has agreed to provide BabyTree with a convertible loan and a revolving credit facility of up to RMB1.55 billion (US$250 million). The principal of the convertible loan portion of the transaction could reach as high as RMB744 million (US$120 million) depending on the working capital needs of BabyTree and certain operating performance criteria being met. The loan will be convertible into a minority interest in BabyTree based on a pre-agreed formula. The revolving credit facility will be RMB806 million (US$130 million), and drawdown by BabyTree will also depend on the working capital needs of BabyTree and certain operating performance criteria being met.
According to BabyTree, BabyTree is the largest online parenting community in China, and is among the largest online parenting communities globally as ranked by traffic volume. Presently the DAU (daily active users) of BabyTree has surpassed 10 million. BabyTree.com, the website of the company, together with its mobile apps “BabyTree Pregnancy” and “BabyTree Footprints,” cover over 80% of pregnancy-stage parents and parents of 0-6 year-old children in China. The “BabyTree Pregnancy” app ranks number one among baby and maternity mobile apps in China.
Jumei International Holding Limited operates as an online retailer of beauty products in the People’s Republic of China. The company offers beauty products, such as cosmetics, skin care, cosmetic applicators, fragrance, and body care products; and beauty products for men, and baby and children. It also provides apparel and other lifestyle products, counting women’s wear, footwear, lingerie, handbags and luggage, men’s wear, sportswear and sporting goods, accessories, home goods, and other lifestyle products, in addition to baby, children, and maternity products; and snacks and health supplements.
Finally, McDonald’s Corporation (NYSE:MCD), decreased -0.07%, to $99.29.
McDonald’s Board of Directors declared a quarterly cash dividend of $0.85 per share of common stock payable on September 16, 2015 to shareholders of record at the close of business on September 1, 2015.
McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2014, it operated 36,258 restaurants, counting 29,544 franchised restaurants comprising 20,774 franchised to conventional franchisees, 5,228 licensed to developmental licensees, and 3,542 licensed to foreign associates; and 6,714 company-operated restaurants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
